Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 11fludarabine phosphate 9Whole-Body Irradiation 8Mycophenolic Acid 7Busulfan 6fludarabine 5Tacrolimus 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Rituximab 4Biopsy 4Azacitidine 4venetoclax 3apixaban 3Cyclosporine 3thymoglobulin 2decitabine and cedazuridine drug combination 2Vorinostat 2Vancomycin 2Tretinoin 2Specimen Handling 2Sirolimus 2Methotrexate 2Lenalidomide 2Injections 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Decitabine 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TAK-243 × Classical hematology × 90 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡